P975: INTERIM ANALYSIS OF PHASE II STUDY OF DARATUMUMAB IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA WHO RECEIVED 1 PRIOR LINE OF THERAPY (KMM1906)

• K. H. Yoo,
• G. W. Gang,
• J. H. Yi,
• M. K. Kim,
• H. J. Kim,
• S.-H. Kim,
• J. S. Park,
• J.-J. Lee,
• C.-K. Min,
• J. H. Lee,
• D. Cho,
• K. Kim

Affiliations

K. H. Yoo

1 Division of Hematology, Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon

G. W. Gang

2 Division of Oncology and Hematology, Department of Internal Medicine, Korea University Medical Center, Seoul

J. H. Yi

2 Division of Oncology and Hematology, Department of Internal Medicine, Korea University Medical Center, Seoul

M. K. Kim

3 Department of Internal Medicine, Yeungnam University College of Medicine, Daegu

H. J. Kim

4 Division of Hematology/Oncology, Department of Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang

S.-H. Kim

5 Department of Internal Medicine, Dong-A University College of Medicine, Busan

J. S. Park

6 Department of Hematology-Oncology, Ajou University School of Medicine, Suwon

J.-J. Lee

7 Department of Hematology-Oncology, Chonnam University Hwasun Hospital, Hwasun

C.-K. Min

8 Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea

J. H. Lee

1 Division of Hematology, Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon

D. Cho

9 Department of Laboratory Medicine and Genetics

K. Kim

10 Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea